阿片类使用障碍药物治疗与自杀死亡率的相关性
该回顾性队列研究纳入2003至2017年超过6万名接受阿片类使用障碍药物治疗(MOUD)的退伍军人事务部患者,评估MOUD与5年内自杀死亡率、外因死亡率及全因死亡率的关系。调整混杂因素后,稳定MOUD期间自杀死亡率风险显著降低(aHR=0.45),外因死亡和全因死亡风险亦降低;MOUD起始期和停止期自杀死亡风险无显著差异。
要点
- 稳定MOUD期间自杀死亡风险显著低于未治疗期(aHR=0.45)。
- 稳定MOUD期间外因死亡和全因死亡风险亦显著降低。
- MOUD起始期和停止期自杀死亡风险与参照组无显著差异。
核心结论
- MOUD治疗与自杀死亡率、外因死亡率及全因死亡率的大幅降低相关。
研究设计与样本
- 回顾性队列研究,纳入2003至2017年退伍军人事务部(VA)超过6万名接受MOUD的患者。
- 暴露分为MOUD起始期(治疗前14天)、停止期(停药前14天)、稳定治疗期和稳定未治疗期(参照组)。
- 主要结局为MOUD启动后5年内的自杀死亡率、外因死亡率和全因死亡率。
主要发现
- 患者平均年龄46.5岁(SD=13.1),男性占92.8%。
- 调整人口学特征、精神与躯体健康状况及医疗服务利用后,稳定MOUD期间自杀死亡aHR=0.45(95%CI=0.32,0.63)。
- 稳定MOUD期间外因死亡aHR=0.35(95%CI=0.31,0.40),全因死亡aHR=0.34(95%CI=0.31,0.37)。
- MOUD起始期自杀死亡aHR=0.55(95%CI=0.25,1.21),停止期aHR=1.38(95%CI=0.82,2.34)。
临床怎么用
- 稳定MOUD治疗与自杀死亡风险降低相关,可能为临床决策提供参考。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Understanding the effectiveness of medication treatment for opioid use disorder to decrease the risk of suicide mortality may inform clinical and policy decisions. The authors sought to describe the effect of medications for opioid use disorder (MOUD) on risk of suicide mortality. METHODS: This was a retrospective cohort study in Department of Veterans Affairs (VA) patients from 2003 to 2017. The authors linked three data sources: the VA Corporate Data Warehouse, Centers for Medicare and Medicaid Services Claims Data, and the VA-Department of Defense Mortality Data Repository. The exposure of interest was MOUD, including starting periods (first 14 days on treatment), stopping periods (first 14 days off treatment), stable time on treatment, and stable time off treatment (reference category). The main outcome measures included suicide mortality, external-cause mortality, and all-cause mortality in the 5 years following initiation of MOUD. RESULTS: Over 60,000 VA patients received MOUD. Patients were typically male (92.8%) and their mean age was 46.5 years (SD=13.1). After adjusting for demographic characteristics, mental health and physical health conditions, and health care utilization, the adjusted hazard ratio during stable MOUD was 0.45 (95% CI=0.32, 0.63) for suicide mortality, 0.35 (95% CI=0.31, 0.40) for external-cause mortality, and 0.34 (95% CI=0.31, 0.37) for all-cause mortality. MOUD starting periods were associated with an adjusted hazard ratio for suicide mortality of 0.55 (95% CI=0.25, 1.21), and MOUD stopping periods were associated with an adjusted hazard ratio for suicide mortality of 1.38 (95% CI=0.82, 2.34). CONCLUSIONS: Treatment with MOUD was associated with a substantial reduction in suicide mortality as well external causes of mortality and all-cause mortality.
引用
- Watts BV, Gottlieb DJ, Riblet NB, et al. Association of Medication Treatment for Opioid Use Disorder With Suicide Mortality. Am J Psychiatry. 2022. PMID: 35360916. doi:10.1176/appi.ajp.2021.21070700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。